Amazon is about to become your neighborhood pharmacy, whether your neighborhood pharmacy likes it or not.
The e-commerce giant announced it will stock Eli Lilly's new weight-loss pill at U.S. kiosks and offer same-day delivery. This isn't just Amazon selling another product, this is Amazon inserting itself into the most lucrative pharmaceutical market in years: GLP-1 weight-loss drugs.
Let's talk about what this actually means. Eli Lilly makes Mounjaro and Zepbound, two of the hottest weight-loss drugs on the market. These aren't cheap: a month's supply can cost over $1,000 without insurance. And now Amazon is making them available with the same convenience as ordering a phone charger.
Who should be worried? CVS, Walgreens, and every other traditional pharmacy chain.
Amazon has been slowly creeping into healthcare for years. They bought PillPack in 2018, launched Amazon Pharmacy in 2020, and now they're moving into high-margin prescription drugs with physical distribution points. The kiosk model is brilliant because it solves the last-mile problem: people don't want to wait for medications to ship, they want them now. Amazon's kiosks give them that immediacy while bypassing traditional pharmacies entirely.
For Eli Lilly, this is a no-brainer. They get access to Amazon's distribution network and customer base, which means more sales. For Amazon, this is a strategic foothold in a market worth hundreds of billions of dollars.
But here's the uncomfortable part: Amazon is becoming a gatekeeper for healthcare access.
Weight-loss drugs are already controversial because of cost and availability. Now Amazon, a company known for ruthless efficiency and data collection, is controlling distribution. What happens when Amazon starts optimizing pricing algorithms for GLP-1s the same way they optimize toothpaste prices? What happens when Amazon's recommendation engine starts pushing weight-loss drugs to customers based on their purchase history?
